Karina Volkova trains in a clinic using a temporary permit that expires in 2027, giving her a narrow window to clear all ...

Weight loss at the time of GLP-1 discontinuation was 10.1% overall, 9.7% for those with T2D, and 11.1% for those without.

Sometimes a strain develops that, while not entirely new, is new enough to spread more efficiently because it is not well ...

Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...

Somatic mutations with effects similar to those seen with VEXAS syndrome are increasingly seen as possible drivers of ...

An analysis of a German multicentre study reveals that women are more likely than men to receive inappropriate diagnostic ...

With indications that ‘“dialysis begets dialysis”’ and can obscure kidney function improvement, a novel trial shows notable ...

A simulation study suggests that routine use of multicancer early detection tests could cut stage IV diagnoses of 14 cancers ...

The regulator backed the medicine after phase 3 data showed dramatic reductions in HAE attacks and sustained disease control ...

The recommendation follows results showing markedly longer time to diagnosis of stage 3 T1D in treated patients, a condition ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...

Older adults with apparent hypothyroidism may or may not need treatment. This second article about thyroid disease in older ...